Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun;23(6):e244.
doi: 10.1016/S1470-2045(22)00265-0.

Clinical features and outcomes of NAFLD-related hepatocellular carcinoma - Authors' reply

Darren Jun Hao Tan  1 , Cheng Han Ng  1 , Mark D Muthiah  2 , Rohit Loomba  3 , Daniel Q Huang  4
Affiliations
Comment

Clinical features and outcomes of NAFLD-related hepatocellular carcinoma - Authors' reply

Darren Jun Hao Tan et al. Lancet Oncol. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse Bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen, Madrigal, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 Bio, Terns Pharmaceuticals, and Viking Therapeutics. His institutions received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes, and Terns Pharmaceuticals. RL is also the co-founder of LipoNexus. DQH has served as an advisory board member for Eisai. All other authors declare no competing interests.

Comment on

MeSH terms

LinkOut - more resources